[Form 4] Vicarious Surgical Inc. Insider Trading Activity

Rhea-AI Filing Summary

Donald F. Tang, a director of Vicarious Surgical Inc. (ticker: RBOT), reported receipt of a stock option on 06/27/2025. The option covers 5,335 underlying shares of Class A common stock with an exercise price of $7.61. The filing states all shares underlying the option will vest on June 27, 2026 or one day prior to the issuer's next annual meeting, whichever is earlier, provided the reporting person remains in service through the vesting date. The Form 4 shows the report was signed by an attorney-in-fact, Erin Checka, on 08/11/2025.

Positive

• Director received a stock option grant covering 5,335 underlying Class A shares, as reported on the Form 4
• Exercise price disclosed: $7.61 per share, providing clear terms in the filing
• Vesting schedule provided: full vesting on June 27, 2026, or one day prior to the issuer's next annual meeting, subject to continued service

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine director equity award; limited immediate cash impact, potential future dilution upon exercise.

The reported transaction is a time-based stock option grant to a director for 5,335 shares at a $7.61 exercise price, documented on a Form 4 filed for RBOT. As a standard compensation tool, this option creates a potential future obligation only if exercised; there is no cash proceeds or immediate change to revenue or earnings reported in this filing. Without company-wide share counts or prior insider holdings in this filing, the absolute dilutive effect cannot be quantified from the document alone. The vesting schedule (by 06/27/2026 or one day prior to the next annual meeting) ties value to continued service, which is a common governance practice.

Corporate Governance Expert

TL;DR: Grant follows typical director compensation patterns; vesting condition aligns with service and shareholder meeting timing.

The Form 4 indicates the option vests within roughly one year, conditioned on continued service, which aligns director incentives with near-term company performance and governance milestones. The filing was executed by an attorney-in-fact, showing standard administrative handling. The document does not disclose grant authorization details, board approval context, or how this award fits within the overall compensation program, so governance implications are limited to the disclosed vesting terms and award mechanics.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tang Donald F

(Last) (First) (Middle)

C/O VICARIOUS SURGICAL INC.

78 FOURTH AVENUE

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vicarious Surgical Inc. [ RBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.61	06/27/2025		A		5,335		(1)	06/26/2035	Class A Common Stock	5,335	$0.00	5,335	D

Explanation of Responses:

1. All of the shares underlying this option will vest on June 27, 2026, or one day prior to the Issuer's next Annual Meeting of Shareholders, whichever is earlier, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Erin Checka, Attorney-in-Fact	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Donald F. Tang report on the RBOT Form 4?

He reported receipt of a stock option on 06/27/2025 covering 5,335 underlying Class A common shares with an exercise price of $7.61.

When do the options vest according to the filing?

All shares underlying the option will vest on June 27, 2026, or one day prior to the issuer's next Annual Meeting of Shareholders, whichever is earlier, subject to continued service.

What is the relationship of the reporting person to Vicarious Surgical (RBOT)?

Donald F. Tang is reported as a Director of Vicarious Surgical Inc. in the Form 4.

Who signed the Form 4 and when was it signed?

The form was signed by Erin Checka, Attorney-in-Fact, on 08/11/2025.

Does the filing show an expiration or other date for the derivative instrument?

The filing includes the date 06/26/2035 in the derivative table as presented in the document.